Radiation
holmium-166 radioembolization
holmium-166 radioembolization is a radiation therapy with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
RADIATION
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
33%
Ph not_applicable
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
Completed1
unknown1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 21 (50.0%)
N/A1 (50.0%)
Trials by Status
completed133%
unknown133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruiting
Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma
NCT06873269
unknownnot_applicable
Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma
NCT05114148
completedphase_2
HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients
NCT03379844
Clinical Trials (3)
Showing 3 of 3 trials
NCT06873269
Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma
NCT05114148Not Applicable
Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma
NCT03379844Phase 2
HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients
All 3 trials loaded
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 3